The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.
Estimated life expectancy > 6 months
Willingness to give an informed consent
Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
Superficial vein thrombosis
Refusal of informed consent > 72 hrs of anticoagulants
Age < 18 years old
Patients with Cancer Associated Thrombosis receiving anticoagulation treatment with a follow-up of 6 months
Cohort
Prospective
Not listed
Recurrent VTE
The primary outcome of the study will include objectively confirmed recurrent VTE (distal and/or proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and/or splanchnic vein thrombosis and/or cerebral venous sinus thrombosis
Overall mortality
Post-enrollment follow-up visits will include documentation of death if occuring at any time during the 6 month follow up period
Clinically relevant bleeding
Post-enrollment follow-up visits will include assessment and documentation of any major and CRNMB and bleeding risk factors at any time during the 6 month follow up period.
Click on the lead sponsor to view all of their trials.
Ottawa Hospital Research Institute
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
